The Plasma Institute of the Logistics Department of Chengdu Military Region was founded in 1969.

Chengdu Shuyang Pharmaceutical Factory was established in 1985.

In 1989, the low-temperature ethanol separation process production line was put into mass production, marking Shuyang’s leading position in protein separation technology among the country

In 1994, it became the first company in the industry to pass both national GMP and ISO9002 quality system certification; the company also obtained approval for production of Human Albumin

In 1998, the company obtained approval for production of Human Immunoglobulin for intravenous injection.
Transferred to the Chengdu Municipal People's Government by the Logistics Department of the Chengdu Military Region.

In 2001, the company joined China Grand Enterprises and was renamed Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

In 2003, Shuyang’s Human Immunoglobulin for intravenous injection was first exported to international markets

In 2004, the company obtained approval for production of Human Tetanus Immunoglobulin

In 2007, Yuanda Shuyang completed the restructuring and acquisition of plasmapheresis stations.

In 2011, the annual plasma collection volume of the Changning plasmapheresis station exceeded 100,000 units, making it the plasmapheresis station with the largest plasma collection volume in the country.

In 2016, the new plant construction project of Yuanda Shuyang Pharmaceutical was officially launched. Yin Li, then deputy secretary of the Sichuan Provincial Party Committee and governor of Sichuan Province, attended the opening ceremony

In 2019, the company grew into a major subsidiary of the Grand Life Science Group

In 2021, the company obtained drug registration approval for Human Fibrinogen

With a total investment of 2.5 billion RMB in 2022 , the highly automated and digital blood products production plant designed and built with a world-class team was fully put into operation.